Skip to main content
. 2012 Apr;14(4):304–314. doi: 10.1111/j.1463-1326.2011.01523.x

Figure 2.

Figure 2

LEAD-5 trial: change in (A) body weight over time, and (B) body weight from baseline [mean (SD)]. Data are last observation carried forward, intent-to-treat population; *Liraglutide vs. insulin glargine (p<0.0001) and placebo (p=0.0001). SD, standard deviation; LEAD, liraglutide effect and action in diabetes. Reprinted with permission from Springer [29].